EXPERT REVIEWS IN MOLECULAR MEDICINE, published by Cambridge University Press, stands at the forefront of research in the fields of Molecular Biology and Molecular Medicine. With an impressive impact factor reflecting its Q1 status in both relevant categories, this journal serves as an essential platform for disseminating cutting-edge reviews and critical assessments that are vital for advancing our understanding of molecular mechanisms in health and disease. Established in 1997 and continuously evolving until 2024, it features contributions from leading experts that highlight emerging trends and innovative methodologies. Researchers, professionals, and students are encouraged to engage with the content, benefiting from the journal’s rigorous peer-review process and its commitment to academic excellence, making it a valuable resource within the scientific community.

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Cancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.

CELLULAR ONCOLOGY is an esteemed open access journal published by SPRINGER since 2004, specializing in the dynamic field of oncological research. With its ISSN 2211-3428 and E-ISSN 2211-3436, this journal plays a pivotal role in disseminating cutting-edge findings and innovative methodologies that address cancer at the cellular level. The journal has consistently achieved high-impact recognition, currently holding a Q2 rating in Cancer Research and Q1 rankings in Medicine (miscellaneous), Molecular Medicine, and Oncology as of 2023. Furthermore, it ranks 56th in oncology medicine and 48th in cancer research according to Scopus, placing it firmly within the top echelons of its field. Published in the Netherlands, with an aim to connect scientists, clinicians, and practitioners worldwide, CELLULAR ONCOLOGY fosters a collaborative environment for researchers to share insights, enhance understanding, and advance treatments. The journal’s open access model ensures that ground-breaking research is freely available, facilitating greater visibility and impact within the scientific community and beyond.

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

Cell Metabolism is an esteemed journal published by CELL PRESS, dedicated to advancing the understanding of metabolic processes within cell biology, molecular biology, and physiology. With an impactful 2023 ranking placing it at Q1 in multiple categories and earning a distinguished position in the top percentiles of its respective fields, this journal serves as an essential resource for researchers, professionals, and students who are investigating the dynamic roles of metabolism in health and disease. Its rigorous peer-review process ensures high-quality publications that reflect the latest advancements in metabolic research. Since its inception in 2005, Cell Metabolism has become a pivotal platform for disseminating critical findings that not only expand scientific knowledge but also foster innovative approaches to tackle metabolic disorders. By prioritizing accessibility and scholarly excellence without the Open Access model, it remains a premier source for cutting-edge research insights.

NEOPLASIA is an esteemed open-access journal dedicated to advancing the field of oncology, published by Elsevier Science Inc. since 1999. With an impressive impact factor and recognition as a Q1 journal in Cancer Research for 2023, it holds a significant position within the scientific community, specifically ranking in the 74th percentile globally in the categories of Biochemistry, Genetics, and Molecular Biology. NEOPLASIA seeks to provide a comprehensive platform for innovative research, covering a wide array of topics in cancer biology, treatment methodologies, and therapeutic advancements. Researchers, professionals, and students are encouraged to utilize this resource, which is easily accessible to foster collaboration and stimulate progress in cancer research. As it converges its efforts towards the future of oncology, this journal is poised to remain at the forefront of transformative discoveries that shape our understanding and treatment of cancer.

PPAR Research, an esteemed journal published by HINDAWI LTD, specializes in the rapidly evolving fields of drug discovery and pharmacology, contributing significantly to the body of research surrounding peroxisome proliferator-activated receptors (PPARs) and their roles in various biochemical processes. With an open access policy implemented since 2006, the journal ensures that its high-quality content is readily available, promoting widespread dissemination of knowledge. Currently ranked in the Q2 category for both Drug Discovery and Medical Pharmacology, it boasts a respectable position within the scientific community, evidenced by its Scopus rankings. PPAR Research serves as an essential resource for researchers, professionals, and students looking to advance their understanding of PPAR biology and its implications in therapeutic development. The journal's commitment to excellence and accessibility makes it a key player in supporting innovative research and critical discussions in the life sciences.

Molecular Metabolism is a premier, open-access journal published by Elsevier, dedicated to advancing the understanding of metabolic processes at the molecular level. With an ISSN of 2212-8778 and a proud presence in Germany, the journal has made significant contributions to the fields of Cell Biology and Molecular Biology, consistently achieving a Q1 ranking in both categories as of 2023. The journal’s scope encompasses cutting-edge research that explores metabolic pathways, their regulation, and implications for human health, underscoring the interplay between metabolism and various biological functions. Researchers and professionals benefit from the journal’s robust visibility, as it ranks #40 among 410 journals in Molecular Biology and #35 among 285 in Cell Biology according to Scopus metrics, placing it in the top 10 percentile in its field. With open access since 2012, Molecular Metabolism ensures that groundbreaking research is available to all, fostering a collaborative and inclusive academic environment. Its commitment to excellence and accessibility makes it an invaluable resource for those invested in metabolic research.